DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Umecta PD (Urea) - Summary



Rx only
For topical use only
Not for ophthalmic use

Umecta is a keratolytic, emollient which is a gentle, yet potent, tissue softener for nails and skin

Each gram of Umecta PD bioadhesive emulsion and topical suspension contains40% urea, sodium hyaluronate 0.3%, BHT, butyrospermum parkii fruit oil, citric acid, dimethylacrylamide (and) acrylic acid (and) polystyrene ethyl methacrylate copolymer, disodium EDTA, glyceryl stearate, glycine soja sterol, helianthus annuus oil, hydroxypropylmethyl cellulose, purified water, sodium citrate, stearic acid.

Umecta PD (UREA) is indicated for the following:

For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns, and calluses, as well as damaged, ingrown and devitalized nails.

See all Umecta PD indications & dosage >>


Media Articles Related to Umecta PD (Urea)

Pioglitazone, Sulfonylureas Safe and Effective in Type 2 Diabetes
Source: Medscape Diabetes & Endocrinology Headlines [2017.09.29]
They may not boast a cardiovascular benefit like other newer drugs, but these drugs can safely be added to metformin to manage type 2 diabetes.
Medscape Diabetes & Endocrinology

more news >>

Published Studies Related to Umecta PD (Urea)

Immunologic effects of hydroxyurea in sickle cell anemia. [2014]
maturation and vaccine responses... CONCLUSIONS: Hydroxyurea does not appear to have significant deleterious effects

Hydroxyurea and growth in young children with sickle cell disease. [2014]
Effects of hydroxyurea (HU) on growth in very young children are not known... CONCLUSIONS: Both groups had normal or near normal anthropometric measures during

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. [2014]
Glucose-lowering treatment options are limited for uncontrolled type 2 diabetes mellitus (T2DM) patients with advanced stages of renal impairment (RI)... These data suggest that linagliptin is a safe and effective glucose-lowering treatment in T2DM patients with moderate-to-severe RI for whom sulphonylurea treatment is no longer sufficient.

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. [2013]
CONCLUSIONS: Findings suggest that canagliflozin may be a new therapeutic tool

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. [2013]
glycaemic control... INTERPRETATION: Sulfonylurea monotherapy lowered HbA1c level more

more studies >>

Clinical Trials Related to Umecta PD (Urea)

Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis [Recruiting]
Dose response curve to define the security and tolerable dose to be used for prevention and treatment of radiodermatitis in patients with breast or head and neck cancer.

Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment [Completed]
In this short-term study a method for the evaluation of the metabolic competency of the urea cycle in vivo will be assessed. In order to monitor the efficacy of new treatment options for patients with urea cycle disorders and to monitor the severity of the disease, a reliable and safe quantitative method for the measurement of the urea cycle flux is required. Urea synthesis will be evaluated by administering sodium [1-13C]-acetate and measuring subsequent incorporation of [13C] label from Na-acetate into urea in healthy volunteers and asymptomatic subjects genetically disposed to urea cycle disorders.

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function [Completed]
This diagnostic study will be performed to investigate the performance of the urea cycle in healthy subjects, asymptomatic carriers of Urea Cycle Disorders (UCD) mutations and subjects with genetically proven urea cycle disorders. The ureagenesis rate will be measured by 13C incorporation assay, a method for in vivo measurement of urea cycle performance with stable isotopes.

Vaginal Fluid Wash in Pre-labour Rupture of Membranes [Recruiting]
The investigators assess in this study the sensitivity of Urea and Creatinine and that of Nitrazine test in vaginal wash after injecting saline in the vagina of patients with pre-labour rupture of membranes

Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis [Not yet recruiting]
This study aims to evaluate therapeutics interventions in radiodermatitis in patients with breast or head and neck cancer. The data collect is going to begin after determining the better dose in a dose-response curve that is being conduct now in the same institution. To evaluate the skin reaction will be applied scale of the Radiation Therapy Oncology Group

(RTOG) - Acute Radiation Morbidity Scoring Criteria, Common Terminology Criteria for Adverse

Events (CTCAE) and Radiation-Induced Skin Reaction Assessment Scale (RISRAS).

more trials >>

Page last updated: 2017-09-29

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017